|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 181816-48-8 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
Fields of Application :
Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors.
| CAS Number: | 181816-48-8 |
| Purity: | >98% |
| Molecular Weight: | 402.44 |
| Molecular Formula: | C21H26N2O6 |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | AVE8062; AVE8062A; AC7700; AVE-8062; AVE-8062A; AC-7700; AVE 8062; AVE 8062A; AC 7700 |
| Chemical Name: | (2S)-2-amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. CA-4-P induces G2/M arrest, thus bringing about cell death by either mitotic catastrophe or apoptosis. Ombrabulin is a vascular disrupting agent. Target: Differently from CA-4-P, Ombrabulin does not act directly on the tumor vessels but instead causes constriction of the arterioles, resulting in complete downstream arrest of the blood flow and tumor. Recently, Ombrabulin in combination with cisplatin was used in a phase III clinical trial for patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy, significantly improving progression-free survival. However, this improvement was not clinically relevant, despite being statistically significant. Ombrabulin disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour activity when combined with cisplatin. The combination of ombrabulin and cisplatin significantly improved progression-free survival; however, it did not show a sufficient clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic option. Predictive biomarkers are needed for the rational clinical development of tumour vascular-disrupting drugs for soft-tissue sarcomas.
References:
COC1=C(C=C(C=C1)/C=C\C2=CC(=C(C(=C2)OC)OC)OC)NC(=O)[C@H](CO)N
